•  
  •  
 

Corresponding Author

Mahmoud Ahmed Elabiad

Document Type

Case Series

Abstract

Background: Ranibizumab is anti-vascular endothelial growth factor (anti-VEGF) agent made for intraocular use, like smaller antibody fragment that can penetrate retina. Intravitreal ranibizumab therapy has been accepted as a predominant treatment for CNV in recent years.

Objective: To assess potential adverse influence of Ranibizumab on choroid, variations in choroidal thickness were measured before & after Ranibizumab cure for CNV.

Patients & methods: This was prospective research, was carried out at ophthalmology department of Al-Azhar University Hospitals on 20 patients from June 2021till December 2021, to monitor changes of choroidal thickness before & after Ranibizumab cure for CNV to assess possible adverse influence of Ranibizumab on choroid.

Results: There was highly statistically significant variations among before injection & after injection as Choroidal thickness. The mean Choroidal thickness before injection was 356.85 ± 127.10 SD with range (154.0 – 632.0), and the mean Choroidal thickness after injection was 235.40 ± 75.60 SD with range (127.0 – 400.0). There was highly statistically significant variation among before injection & after injection according to Central macular thickness. Mean Central macular thickness before injection was 302.80±84.51 SD with range (168–490), and mean Central macular thickness after injection was 250.25±53.44 SD with range (150– 331).

Conclusion: Patients with choroidal neovascularization had a subfoveal choroidal thickness, which was noticeably thicker in impacted eyes than in unimpacted peers SFCT declined substantially after intravitreal ranibizumab administration, and this was associated with marginal reduction in retinal foveal thickness.

Keywords

Subfoveal choroidal thickness; Intravitreal Ranibizumab; Choroidal neovascularization

Download

Share

COinS